Reuters logo
BRIEF-AB Science announces publication of pivotal phase 3 study masitinib results
January 9, 2017 / 7:12 AM / in 9 months

BRIEF-AB Science announces publication of pivotal phase 3 study masitinib results

Jan 9 (Reuters) - AB Science Sa :

* In pivotal phase 3 study masitinib administered at 6 mg/kg/day was significantly superior to placebo

* 4r75 pct response was 18.7 pct for masitinib treatment-arm versus 7.4 pct for placebo treatment-arm

* Subgroup analysis in patients with kit asp816val (d816v) mutation (90 pct of population) also showed a significant response in favour of masitinib Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below